NH SPAC 2 (206640.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Equipment · South Korea · ISIN KR7206640005

Price
9,600.00 KRW
Market cap
208.40 bn KRW
P/E (2025)
8.81
P/S (2025)
1.29
Dividend yield
1.56 %
Net margin
14.59 %
Return on equity (ROE)
9.69 %
Return on assets (ROA)
8.40 %

NH SPAC 2 financials

Fiscal year20242025
Revenue138.16 bn KRW162.09 bn KRW
Gross profit81.80 bn KRW95.98 bn KRW
Operating income25.98 bn KRW28.94 bn KRW
EBIT32.75 bn KRW28.19 bn KRW
Net income27.26 bn KRW23.65 bn KRW
Diluted EPS – continuing operations1,240.44 KRW1,089.60 KRW

Full history since 2014, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About NH SPAC 2

Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testing for various parameters; ExAmplar, a compact real time PCR that detects virus/bacteria quantitatively or qualitatively using ready-to-use cartridges; ichroma-50, an automated immunoassay system with high-throughput; Hemochroma PLUS, a handheld device that can run tests for anemia; portable analyzers ichroma M3 and ichroma M2; and NuActor, an automated nucleic acid extraction system. It also provides compact immunoassay analyzers, including AFIAS-1, AFIAS-3, AFIAS-6, and AFIAS-10; cardiac reagents; cancer reagents; COVID-19 reagents; diagnostic reagents; reagents for hormones, infections, autoimmune, organ functions, molecular diagnostics, therapeutic drug monitoring, and other test items. In addition, the company offers Ichroma TRIAS, ultra-high sensitivity respiratory disease diagnostic equipment; ALFIAS-3, a diagnostic equipment; and SyncNeb. Boditech Med Inc. was founded in 1998 and is headquartered in Chuncheon-si, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.